ArticleJournal of global health2026
Populational analysis of the mortality-to-incidence ratio across 20 cancer groupings in the Russian Federation.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer represents a leading cause of death globally. The mortality to incidence ratio (MIR) may vary across populations, reflecting regional disparities in care. We aimed to determine MIR trends by cancer subtype across the 80 recognised jurisdictions of the Russian Federation between 2008 and 2018. Methods: We used publicly accessible data from the Pyotr Alexandrovich Herzen Moscow Oncology Research Institute from 2008-2018. We used descriptive and linear regression analyses to estimate MIR from crude mortality and incidence rates across geographical regions. Results: Between 2008 and 2018, surrounding adjacent jurisdictions were significantly associated with increased MIRs compared to centring cities. The culturally distinct region of the Republic of Adygea reported outliers in MIR for sigmoid, rectal, and anal cancers (MIR = 0.754; 95% confidence interval (CI) = 0.579, 0.983), lung cancer (MIR = 1.07 (95% CI undefined), breast cancer (MIR = 0.458; 95% CI = 0.341, 0.615), and melanoma (MIR = 0.462; 95% CI = 0.201, 1.059), which was not observed in adjacent predominantly Caucasian-populated/western Krasnodar krai that fully envelops the Republic geographically. Gross domestic product (11-year average), the number of physicians, and the number of oncologists per 10 000 people were significantly negatively associated with increased MIR (P < 0.05). Conclusions: Differences in MIR for cancer have been observed between capital cities and their surrounding jurisdictions, with increased ratios noted in demographically distinct regions such as the Republic of Adygea. This suggests that population-level differences in MIR and subsequent cancer outcomes are influenced by region, culture, and socioeconomic variations. These findings may inform public health policy on intersectional disparities in MIR across different populations in the Russian Federation, with applicability to other countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.